LAWRENCE, Mass., Nov. 11, 2015 /PRNewswire/ -- In honor of
Veteran's Day, NxStage Medical,
Inc. (Nasdaq: NXTM), a leading manufacturer of
dialysis products, is highlighting its commitment to enabling the
delivery of renal replacement therapy (RRT) for the U.S.
military. Given its unique design and features, which include
menu-driven graphical user interface controls, volumetric
balancing, simple button options, integrated cartridges, pre-mixed
dialysate solutions, and simple effluent drainage capability, the
portable NxStage® System One™ is capable of providing access to
renal replacement therapy (RRT) at combat support hospitals to help
severely wounded soldiers with acute kidney injury (AKI).
Improvements in early combat casualty care management are
potentially lifesaving. Recent research1 shows that
early RRT can help patients survive casualties and reduce risks of
early complications of AKI, typically caused by large soft tissue
damage resulting from explosive devices. The results demonstrate
that RRT can be safely applied in a combat hospital environment and
is likely to allow for safe long-range transport to care facilities
in safe havens for even the most critically injured service
members.
"At NxStage, we remain committed to further developing flexible
technologies to give patients access to renal care, wherever
they are," said Jeff Burbank, CEO of
NxStage Medical. "We believe the System One's unique design enables
it to meet the demands and challenges of our military and provide
care to severely wounded soldiers around the world."
For more information about the System One, please
visit www.nxstage.com.
About The NxStage System One
The System One is used to
provide a range of flexible therapy options in hospitals and
dialysis centers. The NxStage System One is also the first
and only truly portable hemodialysis system cleared specifically by
the FDA for home hemodialysis and home nocturnal
hemodialysis. Its simplicity and revolutionary size (just over a
foot tall) are intended to allow convenient use in patients' homes
and give patients the freedom to travel with their therapy. When
combined with the NxStage PureFlow SL Dialysis Preparation System,
patients are able to further simplify, using ordinary tap water to
create dialysis fluid on demand. Unlike conventional hemodialysis
systems, the System One requires no special infrastructure to
operate. Under the guidance of their physician, patients can use
the NxStage System One, with their trained partners, where, how and
when it best meets their needs, including while they are sleeping -
at home or on vacation and at a medically appropriate treatment
frequency. In addition, NxStage's Nx2Me Connected
Health platform collects important NxStage System One and patient
information for flexible viewing, monitoring and reporting
that may improve patient management and simplify alternative site
care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that
develops, manufactures and markets innovative products for the
treatment of ESRD and acute kidney failure. For more information on
NxStage and its products, please visit the Company's website
at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the
quarter September 30, 2015. NxStage is under no obligation to
(and expressly disclaims any such obligation to) update or alter
its forward-looking statements, whether as a result of new
information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
1David Zonies, MD,
MPH, Joseph DuBose, MD, Joel Elterman, MD, Todd
Bruno, MD, Christian
Benjamin, MD, Jeremy Cannon,
MD, and Kevin K. Chung, MD. Early
implementation of continuous renal replacement therapy optimizes
casualty evacuation for combat-related acute kidney injury. J
Trauma Acute Care Surg. 2013; Volume 75, Number 2, Supplement
2.
Logo - http://photos.prnewswire.com/prnh/20150624/225341
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-affirms-commitment-to-provide-access-to-renal-replacement-therapy-to-us-military-with-system-one-300176763.html
SOURCE NxStage Medical, Inc.